Innovation Endeavors
Edit

Innovation Endeavors

http://www.innovationendeavors.com
Last activity: 19.07.2024
Active
Invests in categories: DataPlatformFinTechTechnologyIndustryAdTechAgriTechHealthTechLearnSecurity
Innovation Endeavors is helping entrepreneurs drive a super evolution of industry. A proliferation of data, advanced computation and robotics are converging to accelerate iteration cycles, radically collapsing time. We invest in visionary founders, transformational technology and emergent ecosystems for a new world. We have offices in Silicon Valley, Tel Aviv, and New York City.
Portfolio
69
Mentions
106
Location: United States, California, Palo Alto
Employees: 11-50
Phone:+1 650-853-1236
Founded date: 2010
Investment Type: Venture Capital
Investment Stage: Seed; Series A; Series B; Series C
.

Portfolio 69

DateNameWebsiteTotal RaisedLocation
28.02.2024Parspecparspec.io$11.5MUnited Sta...
13.02.2024Skyloskylo.tech$153MUnited Sta...
13.07.2023Trunk Tool...trunktools.com$9.9MUnited Sta...
23.02.2023Earthly Te...earthly.dev$8.5MUnited Sta...
05.01.2023Citrine In...citrine.io$51.6MUnited Sta...
29.10.2022OWNYowny.com-United Sta...
29.05.2022Machina La...machinalabs.ai$62.3MUnited Sta...
29.05.2022CipherMode...ciphermode.com-United Sta...
29.05.2022Charactercharacterbio.com$18MUnited Sta...
29.05.2022Aro Homesaro.homes$21MUnited Sta...
Show more

Mentions in press and media 106

DateTitleDescription
25.07.2024GRO Biosciences Secures $60 Million to Revolutionize Gout Treatment** **** In the bustling world of biotechnology, innovation is the lifeblood. GRO Biosciences, or GRObio, has just taken a giant leap forward. The company recently announced the closing of an oversubscribed $60.3 million Series B financing round....
19.07.2024GRO Biosciences: Protein Therapeutics Company Raises $60 Million In Series BGRO Biosciences (GRObio), a biotechnology company leveraging synthetic biology to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the closing of an oversubscribed $60.3 million Series B fin...
19.07.2024GRO Biosciences Closes $60M Series B Financing Co-Led by Atlas Venture and Access BiotechnologyProceeds to advance clinical development of lead program for gout, broaden the Company’s pipeline, and expand its genomically recoded organism platform BOSTON–(BUSINESS WIRE)–July 19, 2024– GRO Biosciences Inc. (“GRObio”), a biotechnology c...
25.06.2024Exsilio Therapeutics Launches with $82 Million Series A Financing to Develop Redosable Genomic Medicines for A Broad Range of DiseasesSeries A co-led by Novartis Venture Fund and Delos Capital, with participation from OrbiMed, Insight Partners, J.P. Morgan Life Sciences Private Capital, CRISPR Therapeutics, Innovation Endeavors, Invus, Arc Ventures, and Deep Insight Compa...
12.06.2024Pyte: Computation Security Platform Company Raises $5 MillionPyte, a secure computation platform for data-first global enterprises, today announced $5 million in additional capital, bringing the total funding to over $12 million. This funding round was led by Myriad Venture Partners with participatio...
30.05.2024Weave Bio Launches for AI-Powered Drug Development, Secures $10MWhat You Should Know: – Weave Bio, an AI-native life sciences platform company, announced today the public release of its flagship offering, AutoIND, and $10 million in seed funding co-led by Innovation Endeavors and Magnetic Ventures. – Au...
03.05.2024Karius Revolutionizes Infectious Disease Diagnostics with $100M Funding BoostKarius, a genomic diagnostics powerhouse, has secured a whopping $100 million in Series C funding to expand its groundbreaking Karius Test. This test, a game-changer in infectious disease diagnosis, uses cutting-edge genomic analysis and AI...
02.05.2024Karius Raises $100M in Series C FundingKarius, Inc., a Redwood City, CA-based leader in genomic diagnostics for infectious disease, raised $100m in Series C funding. The round was co-led by Khosla Ventures and new investors 5AM Ventures and Gilde Healthcare. Also investing was n...
25.04.2024Готовится к запуску ИИ-платформа Augment, конкурент GitHub Copilot, с бюджетом в $252 млнК запуску готовится новая ИИ-платформа Augment. Проект с бюджетом в $252 млн позиционируется как конкурент ИИ-помощника для программистов GitHub Copilot. В недавнем опросе StackOverflow 44% инженеров-программистов заявили, что они в настоящ...
24.04.2024Eric Schmidt-backed Augment, a GitHub Copilot rival, launches out of stealth with $252MAI is supercharging coding — and developers are embracing it. In a recent StackOverflow poll, 44% of software engineers said that they use AI tools as part of their development processes now and 26% plan to soon. Gartner estimates that over...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In